Irina A. Lubensky, M.D.
CDP has developed TMAs to assist investigations in breast cancer, melanoma and colorectal carcinoma.
The breast cancer TMAs were designed and prepared using formalin-fixed, paraffin-embedded breast cancer specimens and associated pathological and clinical outcome data collected by the Cooperative Breast Cancer Tissue Resource (CBCTR). The CDP-CBCTR Progression TMA is designed to permit comparisons of biomarker expression across three stages of disease (node negative, node positive, and metastatic). The CDP-CBCTR Prognostic TMA is designed to permit correlations with survival and recurrence outcomes in stage I, II, and III breast cancer. TMAs were designed to ensure high statistical power for validation of breast cancer biomarkers
The melanoma progression TMAs consist of 273 tissue specimens containing nevi, primary melanomas, metastatic melanoma to the lymph node, and visceral and dermal metastatic melanoma. These TMAs are designed to investigate differences in expression of markers in various stages of melanoma progression and should be used as screening arrays
The colon cancer progression TMA has over 350 primary colon cancers and 100 control tissues and is designed for examination of associations of markers with tumor stage, clinical outcome, and other clinical-pathological variables in Stages I-IV
Information about CDP TMAs and other specimen resources is also available though the Specimen Resource Locator Website (http://pluto3.nci.nih.gov/tissue/default.htm).